• Arvinas Inc ARVN.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.53. The mean expectation of twenty one analysts for the quarter was for a loss of $1.02 per share. Wall Street expected results to range from $-1.87 to -22 cents per share.

• Revenue rose 237.4% to $59.20 million from a year ago; analysts expected $65.28 million.

• Arvinas Inc's reported EPS for the quarter was a loss of 63 cents​.

• The company reported a quarterly loss of $45.1 million.

• Arvinas Inc shares had fallen by 1.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Arvinas Inc is $60.00

This summary was machine generated from LSEG data February 11 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)